Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Erlangen
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
2013
|
| Online Access: | Volltext Volltext Volltext |
| Item Description: | Aus: Annals of the Rheumatic Diseases 72.1 (2013): S. 43-50. <http://ard.bmj.com/content/72/1/43> Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively. |
| Physical Description: | 1 Online-Ressource |
| Format: | Langzeitarchivierung gewährleistet, LZA |
Staff View
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043901981 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 161128s2013 gw |||| o||u| ||||||eng d | ||
| 015 | |a 16,O12 |2 dnb | ||
| 016 | 7 | |a 1119450713 |2 DE-101 | |
| 024 | 7 | |a urn:nbn:de:bvb:29-opus4-78386 |2 urn | |
| 035 | |a (OCoLC)965687730 | ||
| 035 | |a (DE-599)DNB1119450713 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BY | ||
| 049 | |a DE-29 | ||
| 082 | 0 | |a 610 |2 23 | |
| 084 | |a 610 |2 sdnb | ||
| 100 | 1 | |a Dougados, Maxime |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders |b 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |c Maxime Dougados, Karsten Kissel, Tom Sheeran, Paul P. Tak, Philip G. Conaghan, Emilio Martín Mola, Georg Schett, Howard Amital, Federico Navarro-Sarabia, Antony Hou, Corrado Bernasconi, T. W. J. Huizinga |
| 264 | 1 | |a Erlangen |b Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) |c 2013 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Aus: Annals of the Rheumatic Diseases 72.1 (2013): S. 43-50. <http://ard.bmj.com/content/72/1/43> | ||
| 500 | |a Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. | ||
| 500 | |a This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively. | ||
| 538 | |a Langzeitarchivierung gewährleistet, LZA | ||
| 700 | 1 | |a Kissel, Karsten |e Verfasser |4 aut | |
| 700 | 1 | |a Sheeran, Tom |e Verfasser |4 aut | |
| 700 | 1 | |a Tak, Paul P. |e Verfasser |4 aut | |
| 700 | 1 | |a Conaghan, Philip G. |e Verfasser |4 aut | |
| 700 | 1 | |a Martín Mola, Emilio |e Verfasser |4 aut | |
| 700 | 1 | |a Schett, Georg |e Verfasser |4 aut | |
| 700 | 1 | |a Amital, Howard |e Verfasser |4 aut | |
| 700 | 1 | |a Navarro-Sarabia, Federico |e Verfasser |4 aut | |
| 700 | 1 | |a Hou, Antony |e Verfasser |4 aut | |
| 700 | 1 | |a Bernasconi, Corrado |e Verfasser |4 aut | |
| 700 | 1 | |a Huizinga, T. W. J. |e Verfasser |4 aut | |
| 856 | 4 | 0 | |u https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-78386 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://d-nb.info/1119450713/34 |x Langzeitarchivierung Nationalbibliothek |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://open.fau.de/handle/openfau/7838 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ebook | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029311208 | ||
Record in the Search Index
| _version_ | 1804176807175389184 |
|---|---|
| any_adam_object | |
| author | Dougados, Maxime Kissel, Karsten Sheeran, Tom Tak, Paul P. Conaghan, Philip G. Martín Mola, Emilio Schett, Georg Amital, Howard Navarro-Sarabia, Federico Hou, Antony Bernasconi, Corrado Huizinga, T. W. J. |
| author_facet | Dougados, Maxime Kissel, Karsten Sheeran, Tom Tak, Paul P. Conaghan, Philip G. Martín Mola, Emilio Schett, Georg Amital, Howard Navarro-Sarabia, Federico Hou, Antony Bernasconi, Corrado Huizinga, T. W. J. |
| author_role | aut aut aut aut aut aut aut aut aut aut aut aut |
| author_sort | Dougados, Maxime |
| author_variant | m d md k k kk t s ts p p t pp ppt p g c pg pgc m e m me mem g s gs h a ha f n s fns a h ah c b cb t w j h twj twjh |
| building | Verbundindex |
| bvnumber | BV043901981 |
| collection | ebook |
| ctrlnum | (OCoLC)965687730 (DE-599)DNB1119450713 |
| dewey-full | 610 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 610 - Medicine and health |
| dewey-raw | 610 |
| dewey-search | 610 |
| dewey-sort | 3610 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02674nmm a2200541zc 4500</leader><controlfield tag="001">BV043901981</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">161128s2013 gw |||| o||u| ||||||eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">16,O12</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1119450713</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">urn:nbn:de:bvb:29-opus4-78386</subfield><subfield code="2">urn</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)965687730</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1119450713</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BY</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dougados, Maxime</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders</subfield><subfield code="b">24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)</subfield><subfield code="c">Maxime Dougados, Karsten Kissel, Tom Sheeran, Paul P. Tak, Philip G. Conaghan, Emilio Martín Mola, Georg Schett, Howard Amital, Federico Navarro-Sarabia, Antony Hou, Corrado Bernasconi, T. W. J. Huizinga</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Erlangen</subfield><subfield code="b">Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)</subfield><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Aus: Annals of the Rheumatic Diseases 72.1 (2013): S. 43-50. <http://ard.bmj.com/content/72/1/43></subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively.</subfield></datafield><datafield tag="538" ind1=" " ind2=" "><subfield code="a">Langzeitarchivierung gewährleistet, LZA</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kissel, Karsten</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sheeran, Tom</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tak, Paul P.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Conaghan, Philip G.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martín Mola, Emilio</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schett, Georg</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Amital, Howard</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Navarro-Sarabia, Federico</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hou, Antony</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bernasconi, Corrado</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huizinga, T. W. J.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-78386</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://d-nb.info/1119450713/34</subfield><subfield code="x">Langzeitarchivierung Nationalbibliothek</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://open.fau.de/handle/openfau/7838</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029311208</subfield></datafield></record></collection> |
| id | DE-604.BV043901981 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:38:03Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029311208 |
| oclc_num | 965687730 |
| open_access_boolean | 1 |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | 1 Online-Ressource |
| psigel | ebook |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) |
| record_format | marc |
| spelling | Dougados, Maxime Verfasser aut Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Maxime Dougados, Karsten Kissel, Tom Sheeran, Paul P. Tak, Philip G. Conaghan, Emilio Martín Mola, Georg Schett, Howard Amital, Federico Navarro-Sarabia, Antony Hou, Corrado Bernasconi, T. W. J. Huizinga Erlangen Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) 2013 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier Aus: Annals of the Rheumatic Diseases 72.1 (2013): S. 43-50. <http://ard.bmj.com/content/72/1/43> Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively. Langzeitarchivierung gewährleistet, LZA Kissel, Karsten Verfasser aut Sheeran, Tom Verfasser aut Tak, Paul P. Verfasser aut Conaghan, Philip G. Verfasser aut Martín Mola, Emilio Verfasser aut Schett, Georg Verfasser aut Amital, Howard Verfasser aut Navarro-Sarabia, Federico Verfasser aut Hou, Antony Verfasser aut Bernasconi, Corrado Verfasser aut Huizinga, T. W. J. Verfasser aut https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-78386 Resolving-System kostenfrei Volltext http://d-nb.info/1119450713/34 Langzeitarchivierung Nationalbibliothek kostenfrei Volltext https://open.fau.de/handle/openfau/7838 Verlag kostenfrei Volltext |
| spellingShingle | Dougados, Maxime Kissel, Karsten Sheeran, Tom Tak, Paul P. Conaghan, Philip G. Martín Mola, Emilio Schett, Georg Amital, Howard Navarro-Sarabia, Federico Hou, Antony Bernasconi, Corrado Huizinga, T. W. J. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |
| title | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |
| title_auth | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |
| title_exact_search | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |
| title_full | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Maxime Dougados, Karsten Kissel, Tom Sheeran, Paul P. Tak, Philip G. Conaghan, Emilio Martín Mola, Georg Schett, Howard Amital, Federico Navarro-Sarabia, Antony Hou, Corrado Bernasconi, T. W. J. Huizinga |
| title_fullStr | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Maxime Dougados, Karsten Kissel, Tom Sheeran, Paul P. Tak, Philip G. Conaghan, Emilio Martín Mola, Georg Schett, Howard Amital, Federico Navarro-Sarabia, Antony Hou, Corrado Bernasconi, T. W. J. Huizinga |
| title_full_unstemmed | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Maxime Dougados, Karsten Kissel, Tom Sheeran, Paul P. Tak, Philip G. Conaghan, Emilio Martín Mola, Georg Schett, Howard Amital, Federico Navarro-Sarabia, Antony Hou, Corrado Bernasconi, T. W. J. Huizinga |
| title_short | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders |
| title_sort | adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders 24 week symptomatic and structural results of a 2 year randomised controlled strategy trial in rheumatoid arthritis act ray |
| title_sub | 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |
| url | https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-78386 http://d-nb.info/1119450713/34 https://open.fau.de/handle/openfau/7838 |
| work_keys_str_mv | AT dougadosmaxime addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray AT kisselkarsten addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray AT sheerantom addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray AT takpaulp addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray AT conaghanphilipg addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray AT martinmolaemilio addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray AT schettgeorg addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray AT amitalhoward addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray AT navarrosarabiafederico addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray AT houantony addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray AT bernasconicorrado addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray AT huizingatwj addingtocilizumaborswitchingtotocilizumabmonotherapyinmethotrexateinadequateresponders24weeksymptomaticandstructuralresultsofa2yearrandomisedcontrolledstrategytrialinrheumatoidarthritisactray |